<p>All patients were followed until an event of cerebral infarction, stroke, death, emigration or end of study at 31 December 2009. Patients in warfarin/no warfarin could belong to both the exposed and non-exposed arm. <sup>a</sup>Patients received warfarin after 30 days or more from incident atrial fibrillation or irregular withdrawal during the study period or until occurrence of an endpoint.</p
<p>Data on patients with warfarin treatment duration of more than 5 years are not shown.</p
Objective To examine the association between warfarin treatment and longitudinal outcomes after isch...
<p>Proportion of continuous warfarin therapy after atrial fibrillation diagnosis in (A) specific age...
<p>This figure depicts the cumulative percentage of warfarin-eligible patients (N = 440) who receive...
Background—Although warfarin is widely recommended to prevent atrial fibrillation-related thromboemb...
Warfarin treatment discontinuation is significant among patients with atrial fibrillation (AF). For ...
Background and Aim Warfarin treatment discontinuation is significant among patients with atrial fibr...
<p>Left: Composite endpoint of stroke, bleeding and death. Right: Readmission with atrial fibrillati...
Whether to resume antithrombotic treatment after oral anticoagulant-related intracerebral haemorrhag...
<p>Patients who received treatments with warfarin or any antiplatelet agent, including aspirin and c...
<p>Left axis illustrates the percentage of AF patients having an event within the first year. Right ...
Whether to resume antithrombotic treatment after oral anticoagulant-related intracerebral haemorrhag...
We explored associations between INR measures and clinical outcomes in patients with AF using warfar...
ObjectivesThe purpose of this study was to understand the possible risk of discontinuation in the co...
BACKGROUND AND PURPOSE: Abruptly discontinuing warfarin may induce a rebound prothrombotic state. ...
<p>Data on patients with warfarin treatment duration of more than 5 years are not shown.</p
Objective To examine the association between warfarin treatment and longitudinal outcomes after isch...
<p>Proportion of continuous warfarin therapy after atrial fibrillation diagnosis in (A) specific age...
<p>This figure depicts the cumulative percentage of warfarin-eligible patients (N = 440) who receive...
Background—Although warfarin is widely recommended to prevent atrial fibrillation-related thromboemb...
Warfarin treatment discontinuation is significant among patients with atrial fibrillation (AF). For ...
Background and Aim Warfarin treatment discontinuation is significant among patients with atrial fibr...
<p>Left: Composite endpoint of stroke, bleeding and death. Right: Readmission with atrial fibrillati...
Whether to resume antithrombotic treatment after oral anticoagulant-related intracerebral haemorrhag...
<p>Patients who received treatments with warfarin or any antiplatelet agent, including aspirin and c...
<p>Left axis illustrates the percentage of AF patients having an event within the first year. Right ...
Whether to resume antithrombotic treatment after oral anticoagulant-related intracerebral haemorrhag...
We explored associations between INR measures and clinical outcomes in patients with AF using warfar...
ObjectivesThe purpose of this study was to understand the possible risk of discontinuation in the co...
BACKGROUND AND PURPOSE: Abruptly discontinuing warfarin may induce a rebound prothrombotic state. ...
<p>Data on patients with warfarin treatment duration of more than 5 years are not shown.</p
Objective To examine the association between warfarin treatment and longitudinal outcomes after isch...
<p>Proportion of continuous warfarin therapy after atrial fibrillation diagnosis in (A) specific age...